Comparative analysis of coronavirus disease 2019 and diabetes in mucormycosis: a scoping review
Vergleichende Analyse von COVID-19 und Diabetes bei Mukormykose: Scoping Review
Frontiers in Cellular and Infection Microbiology · 09.11.2026 · 16
DOI: 10.3389/fcimb.2026.1961579 ↗Auf einen Blick
Die Scoping-Review beschreibt klinische und radiologische Merkmale von ROCM in vier Subgruppen nach Diabetes- und COVID-19-Status. Meist lagen unspezifische Sinonasal-Symptome und Stadien IV–V vor.
Fragestellung
Wie prägen Diabetes und COVID-19 den klinischen Verlauf, die radiologische Stadieneinteilung, die Behandlung und die Outcomes von ROCM?
Methode
Scoping Review nach PRISMA-ScR; Suche in PubMed und Web of Science (Januar 2010–August 2025). 155 Studien mit 258 ROCM-Patient:innen.
Ergebnisse
Diabetes mellitus war die häufigste Komorbidität (70,9 %), gefolgt von COVID-19 (38,4 %). Am häufigsten dokumentiert waren chirurgisches Debridement plus systemisches Amphotericin B; die prognostische Rolle von Kortikosteroiden blieb unklar.
Einschränkungen
Der prognostische Stellenwert von Kortikosteroiden blieb unaufgelöst; verlaufs- und stadienbezogene Angaben waren nicht standardisiert berichtet.
Schlussfolgerung der Autor:innen
Die Autor:innen beschreiben klinische und radiologische Merkmale von ROCM in vier Wirtskonstellationen. Sie sehen Bedarf für standardisierte Bildgebung sowie prospektive, multizentrische Kohorten.
Kernaussagen
- ROCM meist mit unspezifischen Sinonasal-Symptomen und Stadien IV–V
- Diabetes (70,9 %) und COVID-19 (38,4 %) häufige Begleitfaktoren
- Debridement plus systemisches Amphotericin B am häufigsten dokumentiert
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Scoping Review in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 09.11.2026. Verfasst von Mei Liu und 4 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Rhino-orbital-cerebral mucormycosis (ROCM) has re-emerged as a serious threat since the coronavirus disease 2019 (COVID-19) pandemic. How diabetes and COVID-19 jointly shape its clinical course remains poorly characterized.
Objective
This scoping review aimed to map the clinical features, radiological staging, treatment, and outcomes of ROCM across subgroups defined by diabetes and COVID-19 status.
Methods
Following PRISMA-ScR guidelines, we searched PubMed and Web of Science (January 2010–August 2025), screening 769 records and including 155 studies with 258 ROCM patients. Cases were divided into four subgroups according to diabetes status and the presence of COVID-19-associated mucormycosis (CAM): diabetic CAM, diabetic non-CAM, non-diabetic CAM, and non-diabetic non-CAM. Data were described and summarized by subgroup.
Results
Diabetes mellitus was the most common comorbidity (70.9%), followed by COVID-19 (38.4%), with cases predominantly reported from Asia. Across all subgroups, early presentations were mainly nonspecific sinonasal symptoms. Radiological staging using the Ebaid system showed that most cases were diagnosed at intermediate-to-advanced stages (predominantly Stage IV–V). Surgical debridement combined with systemic amphotericin B was the most frequently documented treatment, while severity-stratified regimens were rarely reported. The prognostic role of corticosteroids in COVID-19-related cases remained unresolved. Non-diabetic non-CAM patients showed a distinct immunocompromised profile, with hematologic malignancies and transplant-related immunosuppression more prevalent.
Conclusions
This review describes the clinical and radiological characteristics of ROCM across four host backgrounds. The findings suggest that clinicians should not rely solely on classic clinical signs and support the use of standardized imaging assessment for earlier detection. Prospective, multicenter cohorts with standardized staging and outcome reporting are needed to better characterize ROCM and inform severity-based management.
Zitieren
APA
Liu, M., Lei, D., Zhang, C., Xu, Z., & Xu, Z. (2026). Comparative analysis of coronavirus disease 2019 and diabetes in mucormycosis: a scoping review. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1961579
Vancouver
Liu M, Lei D, Zhang C, Xu Z, Xu Z. Comparative analysis of coronavirus disease 2019 and diabetes in mucormycosis: a scoping review. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1961579
BibTeX
@article{Liu2026,
author = {Liu, Mei and Lei, Dan and Zhang, Chunyang and Xu, Zucai and Xu, Zhongxiang},
title = {Comparative analysis of coronavirus disease 2019 and diabetes in mucormycosis: a scoping review},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1961579}
}
EUVIMED